Skip to main content

Table 1 Clinical characteristics of PsA participants

From: Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study

 

PsA (135)

PsA 1 year Retention (107)

PsA 1 year suspension (28)

p

PsA 2 year Retention (94)

PsA 2 year Suspension (41)

p

Age

56 (47–64)

55 (46–63)

61 (51.5–65)

0.11

55.5 (46–62)

61 (48–65)

0.12

Female (%)

59.26

53.27

82.14

0.006

55.32

68.29

0.16

Disease duration (months)

84 (48–144)

80 (48–144)

111.5 (52–150)

0.41

80 (48–144)

97 (51–144)

0.69

BMI

26.6 (24.6–30.2)

26.4 (24.35–30.07)

27.14 (25–31.91)

0.60

26.2 (24.2–29.7)

27.2 (25–31.2)

0.40

Fibromyalgia (%)

29.6

22.22

57.69

 < 0.0001

21.84

47.37

0.004

Smokers (%) Yes

23.88

24.53

21.43

0.62

26.88

17.07

0.005

ex

6.7

5.66

10.71

 

2.15

17.07

 

Peripheral arthritis (%)

95.56

94.39

100

0.20

93.62

100

0.098

Axial involvement (%)

48.89

46.73

57.14

0.33

48.94

48.78

0.99

Enthesitis (%)

35.56

35.51

35.71

0.98

36.17

34.15

0.82

Dactylitis (%)

14.07

14.95

10.71

0.57

15.96

9.76

0.34

Psoriasis (%)

74.07

74.44

71.43

0.72

74.47

73.17

0.87

Nail psoriasis (%)

12.59

14.02

7.14

0.33

14.89

7.32

0.22

csDMARDs use (%)

49.63

47.66

57.14

0.37

44.68

60.98

0.08

bDMARDs use(%)

74.07

71.96

82.14

0.27

71.28

80.49

0.26

Ccs (%)

22.96

18.69

39.29

0.02

18.09

34.15

0.04

NSAIDs (%)

34.81

30.84

50.00

0.06

31.91

41.46

0.24

SNRI (%)

7.41

6.54

10.71

0.45

6.38

9.76

0.49

Anticonvulsivant drugs use (%)

8.15

7.48

10.71

0.58

7.45

9.76

0.65

TJ/68

2 (0–6)

1 (0–5)

3.5 ( 0–9)

0.08

1 (0–4)

4 (0–9)

0.01

SJ/66

0 (0–0)

0 (0–0)

0 (0–1)

0.03

0 (0–0)

0 (0–1)

0.051

PtGA

5 (2–7)

4.5 (2–7)

7 (5–8)

0.002

4 (2–7)

7 (5–8)

0.0003

PP

6 (3–8)

5 (1–7)

8 (6–9)

0.0005

5 (1–7)

8 (5–9)

 < 0.0001

EGA

1 (0–2)

1 (0–2)

2 (1–3)

0.012

0.5 (0–2)

2 (1–3)

0.001

CRP

0.37 (0.14–0.8)

0.3 (0.12–0.64)

0.45 (0.31–0.92)

0.0351

0.315 (0.13–0.73)

0.4 (0.21–0.87)

0.33

DAPSA

13.34 (5.21–22.2)

11.5 (3.4–21.51)

20.31(11.78–23.25)

0.0065

11.06 (3.36–19.85)

20.3 (11.56–23.86)

0.0011

PCS

18 (6–31)

16 (5–29)

29.5 (17–38.5)

0.0001

16 (5–28)

29 (12–38)

0.0002

Helplessness

9 (2–14)

7 (2.12)

13(9–26)

0.0001

7 (2–11)

13 (5–16)

0.0004

Rumination

8 (2–13)

6 (2–12)

13(7–26)

0.0003

6 (2–11)

12.5 (5–16)

0.0005

Magnification

3 (1–5)

2 (1–5)

5 (2–6)

0.0059

2 (1–4)

4 (2–6)

0.0127

HADS anxiety

7 (3–11)

5 (3–10)

9.5 (7–14.5)

0.0002

5 (3–10)

9 (4.14)

0.003

HADS depression

4 (1–8)

3.5 (1–7)

7 (3–10)

0.0091

3 (1–7)

6 (2–10)

0.02

Acceptance and Action Questionnaire II (AAQ)

14 (9–24)

12 (9–22)

22 (9–30)

0.026

12 (9–22)

20 (9–28)

0.07

Trait Hope Scale (THS)

24 (21–26)

24 (21.5–26)

22 (16.5- 25)

0.0392

24 (22–26)

22 (17–25)

0.02

THS agency

12 (10–13)

12 (10–13)

11 (7.5- 12)

0.0361

12 (11–13)

12 (8–12)

0.1

THS pathway

12 (11–13)

12 (11–14)

11 (8.5–13)

0.0449

12 (11–14)

11 (85–13)

0.01

  1. PsA Psoriatic Arthritis, BMI Body Mass Index, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, bDMARDs biologic disease-modifying anti-rheumatic drugs, CCS corticosteroids, NSAIDs Non-steroidal anti-inflammatory drugs, SNRI Serotonin–norepinephrine reuptake inhibitor, TJ tender joints, SJ swollen joints, PtGA patient global assessment, PP patient pain, EGA Examiner global assessment, CRP C-reactive protein, DAPSA Disease Activity in PSoriatic Arthritis, PCS Pain Catastrophizing Scale, HADS Hospital Anxiety and Depression Scale
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us